Investor Presentaiton

Focus for the remainder of FY22 and outlook $ AFTpharmaceuticals Further drive international sales ■ ◉ Accelerate number of new countries in which Maxigesic is launched Growing sales in newly launched markets such as Canada, Germany, Switzerland Launch new line extensions - Maxigesic IV, Hot Drink, Oral Liquid Extend international licensing ■ Finalise Maxigesic licensing agreement discussions in Brazil, China and Japan Drive Australia and New Zealand sales ◉ Drive Maxigesic sales and line extensions in AU & NZ such as hot drink Ongoing in-licensing to expand ANZ business ■ Targeting the launch of circa 30 products before the end of FY23 Financial outlook Guidance for FY22 operating profit of $18 million to $23 million reaffirmed for the year to 31 March 2022, assuming the maintenance of margins and targeted sales outlook Dividend policy remains on the agenda as we progress debt reduction to the target of $25 million to $30 million and linked to underlying earnings progress Page 19

View entire presentation